OSGIX
Price
$40.45
Change
-$0.16 (-0.39%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

OSGIX vs RPTIX

Header iconOSGIX vs RPTIX Comparison
Open Charts OSGIX vs RPTIXBanner chart's image
JPMorgan Mid Cap Growth A
Price$40.45
Change-$0.16 (-0.39%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
OSGIX vs RPTIX Comparison Chart
Loading...
VS
OSGIX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OSGIX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. OSGIX (11.1B). RPTIX pays higher dividends than OSGIX: RPTIX (0.18) vs OSGIX (0.00). OSGIX was incepted earlier than RPTIX: OSGIX (33 years) vs RPTIX (9 years). OSGIX is a more actively managed with annual turnover of: 45.00 vs. RPTIX (21.70). OSGIX has a lower initial minimum investment than RPTIX: OSGIX (1000) vs RPTIX (500000). OSGIX annual gain was more profitable for investors over the last year : 23.10 vs. RPTIX (14.81). OSGIX return over 5 years is better than : 23.93 vs. RPTIX (15.09).
OSGIXRPTIXOSGIX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence33 years9 years-
Gain YTD8.0119.12788%
Front LoadN/AN/A-
Min. Initial Investment10005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets11.1B31.4B35%
Annual Yield % from dividends0.000.18-
Returns for 1 year23.1014.81156%
Returns for 3 years-13.10-13.5797%
Returns for 5 years23.9315.09159%
Returns for 10 years49.59N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp